Stockscreener 앱 받기
2.32
18.60%
-0.53
시장 영업 전:
2.52
0.20
+8.62%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Measuring Cabaletta Bio Inc.’s beta against major indicesMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Cabaletta Bio Inc. stock trendline breakdown2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus
Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener
Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus
Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener
Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times
What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
What candlestick patterns are forming on Cabaletta Bio Inc.July 2025 Gainers & Precise Buy Zone Identification - newser.com
Published on: 2025-10-09 01:46:57 - newser.com
How to use Fibonacci retracement on Cabaletta Bio Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Myasthenia Gravis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma - Barchart.com
Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha
Using fundamentals and technicals on Cabaletta Bio Inc.July 2025 Recap & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Cabaletta Bio Inc. with AIPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Published on: 2025-10-01 06:55:18 - newser.com
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Published on: 2025-09-29 01:01:46 - newser.com
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
What analysts say about Cabaletta Bio Inc stockEarnings Beat Highlights & Outstanding Portfolio Tips - earlytimes.in
5.74%
자본화:
|
볼륨(24시간):